Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-26 | Mr. Vounatsos, 55, has served as our Chief Executive Officer and one of our directors since January 2017. Prior to that, from April 2016 to December 2016, he served as our Executive Vice President, Chief Commercial Officer. Mr. Vounatsos receives no compensation for his service on our Board of Directors. |
| 2018-04-27 | Mr. Vounatsos, 56, has served as our Chief Executive Officer and one of our directors since January 2017. Prior to that, from April 2016 until his appointment as our Chief Executive Officer, he served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris. Mr. Vounatsos has significant knowledge and experience with respect to the biotechnology, healthcare and pharmaceutical industries, a comprehensive leadership background resulting from service as an executive in the pharmaceutical industry and studied medicine as part of his educational background. Biogen Committee Memberships: None. 2017 Director Compensation: Mr. Vounatsos, our Chief Executive Officer, receives no compensation for his service on our Board of Directors. |
| 2019-04-30 | Mr. Vounatsos has served as our Chief Executive Officer and one of our directors since January 2017. Prior to that, from April 2016 until his appointment as our Chief Executive Officer, he served as our Executive Vice President, Chief Commercial Officer. |
| 2020-04-20 | Mr. Vounatsos has served as our Chief Executive Officer and one of our directors since January 2017... Mr. Vounatsos, our Chief Executive Officer, receives no compensation for his service on our Board of Directors. |
| 2021-04-23 | Mr. Vounatsos has served as our Chief Executive Officer and one of our directors since January 2017... Mr. Vounatsos, our Chief Executive Officer, receives no compensation for his service on our Board of Directors. |
| 2022-04-29 | Mr. Vounatsos has served as our Chief Executive Officer and one of our directors since January 2017... Mr. Vounatsos, our Chief Executive Officer, receives no compensation for his service on our Board of Directors. |
| Filing Date | Source Excerpt |
|---|---|
| 2020-03-11 | Michel Vounatsos: Age 58; Principal Occupation: Chief Executive Officer of Biogen Inc. Director of PerkinElmer since March 2020. ... Mr. Vounatsos joins our board with significant knowledge and broad-based experience with respect to the biotechnology, healthcare and pharmaceutical industries, as well as a comprehensive global leadership background resulting from service as an executive in the pharmaceutical industry and his educational background in medicine and business. |
| 2021-03-10 | Michel Vounatsos: Age 59; Principal Occupation: Chief Executive Officer of Biogen Inc. Director of PerkinElmer since 2020. Member of the audit committee. ... 2020 Director Compensation table shows total compensation of $296,646. |
| 2022-03-09 | Michel Vounatsos: Age 60; Principal Occupation: Chief Executive Officer of Biogen Inc., a pioneering world leader in the discovery, development and delivery of innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related adjacencies. Director of PerkinElmer since 2020. Member of the audit committee. ... 2021 Director Compensation ... Michel Vounatsos Fees Earned or Paid in Cash($): 90,000, Stock Awards($): 184,925, All Other Compensation($): 0, Total ($): 274,924. |
| 2023-03-08 | Michel Vounatsos: Age 61; Principal Occupation: Former Chief Executive Officer of Biogen Inc. Director of PerkinElmer since 2020. Chair of the nominating and governance committee and member of the audit committee. 2022 Director Compensation: Michel Vounatsos - Total: $290,045. |
| 2024-03-13 | Michel Vounatsos: Age 62; Principal Occupation: Former Chief Executive Officer of Biogen Inc. Director of Revvity since 2020. Chair of the nominating and corporate governance committee and member of the audit committee. ... Mr. Vounatsos brings to our board significant knowledge and broad-based experience with respect to the biotechnology, healthcare and pharmaceutical industries. ... 2023 Director Compensation ... Michel Vounatsos Fees Earned or Paid in Cash($) 105,000 Stock Awards($) 200,068 Total ($) 305,068 |
| 2025-03-12 | Former Chief Executive Officer, Biogen Inc. |
Data sourced from SEC filings. Last updated: 2026-02-03